Publications by authors named "Kouichirou Saisyo"
Background: Pneumococcal pneumonia is the most frequent form of pneumonia. We herein assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in the prevention of pneumonia overall in rheumatoid arthritis (RA) patients at risk for infections. We hypothesized that PPSV23 vaccination is superior in preventing pneumococcal pneumonia compared with placebo in RA patients.
View Article and Find Full Text PDFVaccination against Streptococcus pneumoniae is recommended for rheumatoid arthritis (RA) patients receiving immunosuppressive treatments. The objective of this study was to evaluate the humoral response to 23-valent pneumococcal polysaccharide vaccination (PPSV23) in RA patients receiving methotrexate (MTX) alone or in combination with a tumor necrosis factor inhibitor, golimumab (GOM).PPSV23 was given to 114 RA patients, who were classified into three groups: RA control (n = 35), MTX alone (n = 55), and GOM + MTX (n = 24).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the immune response of rheumatoid arthritis (RA) patients receiving abatacept (ABT) after vaccination with the 23-valent pneumococcal polysaccharide (PPSV23).
- Patients receiving PPSV23 showed significant increases in antibody levels across all treatment groups, but those on ABT had lower specific IgG responses.
- No significant adverse effects were reported, indicating that while immune responses varied, the functionality of antibodies remained consistent across groups.
Introduction: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA.
Methods: Patients with RA (n = 133) were vaccinated with PPSV23.